Contract Option Exercises — March 29, 2026

$699M obligated (53% of total) with $493M outlayed supports Leidos and Carahsoft through 2028-2029 via full commitments.

$288M in fully obligated FFP contracts to 2027 for IDEMIA passports and NISA pension investments, with $44M outlayed on latter.

$347M fully outlayed for Family Endeavors ORR influx care to 2025, but T&M limits scalability.

$0 outlayed on $204M IDEMIA despite 9-year tenure signals potential delays in State Dept funding/execution.

FFP structures on $753M (Carahsoft, IDEMIA, NISA) expose to cost overruns amid 5-10 year horizons to 2029.

T&M on $347M Family Endeavors invites agency cost scrutiny; nonprofit status caps returns.

$5.8B+ unexercised options (e.g., Carahsoft $1.6B, Family $3B) across all contracts offer multi-fold revenue expansion.

HHS $128M + $77M remaining outlays signal ongoing health R&D/software demand through 2029.

NISA $40M remaining outlays fully match base+options to 2027 in stable pension mgmt.

53% of value in software publishing (NAICS 511210) and biomed R&D (NAICS 541715) underscores sustained federal health spending.

80%+ of contracts extend 2-10 years to 2029 with full obligations, favoring security printing and asset mgmt.

{"entity"=>"IDEMIA National Security Solutions", "reason"=>"$204M obligation with $0 outlayed after 9 years flags execution risks in State Dept passports.", "trigger"=>"outlay >$10M/quarter or termination"}

{"entity"=>"Carahsoft Technology", "reason"=>"Largest $465M HHS award with $128M remaining and $1.6B options upside.", "trigger"=>"options exercised >$500M"}

{"entity"=>"Leidos Holdings (Biomedical sub)", "reason"=>"$77M remaining on $234M fully obligated to 2029 provides low-risk R&D visibility.", "trigger"=>"subaward changes >5% of value"}